Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Urology Reports
Published in: Current Urology Reports 5/2013

01-10-2013 | Lower Urinary Tract Symptoms and Voiding Dysfunction (G Badlani and H Goldman, Section Editors)

Current Recommendations for Bladder Instillation Therapy in the Treatment of Interstitial Cystitis/Bladder Pain Syndrome

Authors: Marc A. Colaco, Robert J. Evans

Published in: Current Urology Reports | Issue 5/2013

Login to get access

Abstract

Bladder instillation therapy refers to the direct introduction of medication into the bladder and is a common treatment modality for patients with interstitial cystitis/bladder pain syndrome (IC/BPS) who have failed conservative and oral therapies. The current American Urological Association (AUA) recommendations list three medications as options for IC/BPS instillation therapy: dimethyl sulfoxide, heparin, and lidocaine. The purpose of this review is to examine the evidence behind the recommendations for these medications. We also examine several historical or experimental therapies that do not hold recommendations but are still used on rare occasion. Finally, we discuss our bladder instillation strategies as well as potential future research and development in intravesicular therapy.
Literature
1.
•• Hanno PM et al. AUA guideline for the diagnosis and treatment of interstitial cystitis/bladder pain syndrome. J Urol. 2011;185:2162–70. This document reflects all the current guidelines and recommendations from the AUA regarding interstitial cystitis/bladder pain syndrome.PubMedCrossRef
2.
Shirley SW, Stewart BH, Mirelman S. Dimethyl sulfoxide in treatment of inflammatory genitourinary disorders. Urology. 1978;11:215–20.PubMedCrossRef
3.
Kim R, Liu W, Chen X, Kreder KJ, Luo Y. Intravesical dimethyl sulfoxide inhibits acute and chronic bladder inflammation in transgenic experimental autoimmune cystitis models. J Biomed Biotechnol. 2011;2011:937061.PubMed
4.
Shiga K et al. Dimethyl sulphoxide relaxes rabbit detrusor muscle by decreasing the Ca2+ sensitivity of the contractile apparatus. Br J Pharmacol. 2007;151:1014–24.PubMedCrossRef
5.
Moldwin RM, Evans RJ, Stanford EJ, Rosenberg MT. Rational approaches to the treatment of patients with interstitial cystitis. Urology. 2007;69:S73–81.CrossRef
6.
Hohlbrugger G, Lentsch P. Intravesical ions, osmolality and pH influence the volume pressure response in the normal rat bladder, and this is more pronounced after DMSO exposure. Eur Urol. 1985;11:127–30.PubMed
7.
Stav K, Beberashvili I, Lindner A, Leibovici D. Predictors of response to intravesical dimethyl-sulfoxide cocktail in patients with interstitial cystitis. Urology. 2012;80:61–5.PubMedCrossRef
8.
Parkin J, Shea C, Sant GR. Intravesical dimethyl sulfoxide (DMSO) for interstitial cystitis–a practical approach. Urology. 1997;49:105–7.PubMedCrossRef
9.
Barker SB, Matthews PN, Philip PF, Williams G. Prospective study of intravesical dimethyl sulphoxide in the treatment of chronic inflammatory bladder disease. Br J Urol. 1987;59:142–4.PubMedCrossRef
10.
Ghoniem GM, McBride D, Sood OP, Lewis V. Clinical experience with multiagent intravesical therapy in interstitial cystitis patients unresponsive to single-agent therapy. World J Urol. 1993;11:178–82.PubMedCrossRef
11.
Rössberger J, Fall M, Peeker R. Critical appraisal of dimethyl sulfoxide treatment for interstitial cystitis: discomfort, side-effects and treatment outcome. Scand J Urol Nephrol. 2005;39:73–7.PubMedCrossRef
12.
• Perez-Marrero R, Emerson LE, Feltis JT. A controlled study of dimethyl sulfoxide in interstitial cystitis. J Urol. 1988;140:36–9. One of the main randomized clinical trials showing the efficacy of DMSO.PubMed
13.
• Peeker R, Haghsheno MA, Holmäng S, Fall M. Intravesical bacillus Calmette-Guerin and dimethyl sulfoxide for treatment of classic and nonulcer interstitial cystitis: a prospective, randomized double-blind study. J Urol. 2000;164:1912–5. discussion 1915–1916. One of the main randomized clinical trials showing the efficacy of DMSO.PubMedCrossRef
14.
Slobodov G et al. Abnormal expression of molecular markers for bladder impermeability and differentiation in the urothelium of patients with interstitial cystitis. J Urol. 2004;171:1554–8.PubMedCrossRef
15.
Hurst RE et al. A deficit of chondroitin sulfate proteoglycans on the bladder uroepithelium in interstitial cystitis. Urology. 1996;48:817–21.PubMedCrossRef
16.
Hanno PM, Fritz R, Wein AJ, Mulholland SG. Heparin as antibacterial agent in rabbit bladder. Urology. 1978;12:411–5.PubMedCrossRef
17.
Kyker KD, Coffman J, Hurst RE. Exogenous glycosaminoglycans coat damaged bladder surfaces in experimentally damaged mouse bladder. BMC Urol. 2005;5:4.PubMedCrossRef
18.
19.
• Parsons CL, Housley T, Schmidt JD, Lebow D. Treatment of interstitial cystitis with intravesical heparin. Br J Urol. 1994;73:504–7. The first major study demonstrating the efficacy of intravesicular heparin.PubMedCrossRef
20.
Parsons CL. Successful downregulation of bladder sensory nerves with combination of heparin and alkalinized lidocaine in patients with interstitial cystitis. Urology. 2005;65:45–8.PubMedCrossRef
21.
Butrick CW, Sanford D, Hou Q, Mahnken JD. Chronic pelvic pain syndromes: clinical, urodynamic, and urothelial observations. Int Urogynecol J Pelvic Floor Dysfunct. 2009;20:1047–53.PubMedCrossRef
22.
Welk BK, Teichman JMH. Dyspareunia response in patients with interstitial cystitis treated with intravesical lidocaine, bicarbonate, and heparin. Urology. 2008;71:67–70.PubMedCrossRef
23.
Interstitial Cystitis Association. Bioniche trial. 2003.
24.
Reece JB, Urry L, Cain M, Wasserman S, Minorsky P, Jackson R. Campbell biology (9th edition; International edition.). Harlow: Pearson Education; 2011.
25.
Davis EL, El Khoudary SR, Talbott EO, Davis J, Regan LJ. Safety and efficacy of the use of intravesical and oral pentosan polysulfate sodium for interstitial cystitis: a randomized double-blind clinical trial. J Urol. 2008;179:177–85.PubMedCrossRef
26.
Henry RA. Re: safety and efficacy of the use of intravesical and oral pentosan polysulfate sodium for interstitial cystitis: a randomized double-blind clinical trial. Davis EL, El Khoudary SR, Talbott EO, Davis J, Regan LJ. J Urol 2008; 179: 177–185. J Urol. 180, 411–412; author reply 412–413 (2008).
27.
Nickel JC et al. A real-life multicentre clinical practice study to evaluate the efficacy and safety of intravesical chondroitin sulphate for the treatment of interstitial cystitis. BJU Int. 2009;103:56–60.PubMedCrossRef
28.
• Nickel JC et al. Intravesical alkalinized lidocaine (PSD597) offers sustained relief from symptoms of interstitial cystitis and painful bladder syndrome. BJU Int. 2009;103:910–8. The major study in the demonstrating the efficacy of intravesicular lidocaine.PubMedCrossRef
29.
Nickel JC et al. Continuous intravesical lidocaine treatment for interstitial cystitis/bladder pain syndrome: safety and efficacy of a new drug delivery device. Sci Transl Med. 2012;4:143ra100.PubMedCrossRef
30.
Boucher W et al. Intravesical nanocrystalline silver decreases experimental bladder inflammation. J Urol. 2008;179:1598–602.PubMedCrossRef
31.
Chancellor MB, De Groat WC. Intravesical capsaicin and resiniferatoxin therapy: spicing up the ways to treat the overactive bladder. J Urol. 1999;162:3–11.PubMedCrossRef
32.
Payne CK et al. Intravesical resiniferatoxin for the treatment of interstitial cystitis: a randomized, double-blind, placebo controlled trial. J Urol. 2005;173:1590–4.PubMedCrossRef
33.
Chen TYH, Corcos J, Camel M, Ponsot Y, Tu LM. Prospective, randomized, double-blind study of safety and tolerability of intravesical resiniferatoxin (RTX) in interstitial cystitis (IC). Int Urogynecol J Pelvic Floor Dysfunct. 2005;16:293–7.PubMedCrossRef
34.
Peters K et al. The efficacy of intravesical Tice strain bacillus Calmette-Guerin in the treatment of interstitial cystitis: a double-blind, prospective, placebo controlled trial. J Urol. 1997;157:2090–4.PubMedCrossRef
35.
Peters KM, Diokno AC, Steinert BW, Gonzalez JA. The efficacy of intravesical bacillus Calmette-Guerin in the treatment of interstitial cystitis: long-term followup. J Urol. 1998;159:1483–6. discussion 1486–1487.PubMedCrossRef
36.
Mayer R et al. A randomized controlled trial of intravesical bacillus calmette-guerin for treatment refractory interstitial cystitis. J Urol. 2005;173:1186–91.PubMedCrossRef
37.
Izes JK, Bihrle 3rd W, Thomas CB. Corticosteroid-associated fatal mycobacterial sepsis occurring 3 years after instillation of intravesical bacillus Calmette-Guerin. J Urol. 1993;150:1498–500.PubMed
38.
Lamm DL et al. Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. J Urol. 1992;147:596–600.PubMed
39.
Nickel JC. Placebo controlled study of safety, tolerability, and efficacy of LiRIS in women with interstitial cystitis, followed by open-label extension. IN: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000. Available from: http://​clinicaltrials.​gov/​ct2/​show/​NCT01475253.​ Cited 2013 Sept
40.
Haifler M, Assaf-Harofeh Medical Center. DMSO Efficacy in IC/PBS patients during and after treatment IN: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000. Available from: http://​www.​clinicaltrials.​gov/​ct2/​show/​NCT01074567.​ NCT identifier:01074567. Cited 2013 Sept.
41.
Fraser MO, Chuang YC, Tyagi P, et al. Intravesical liposome administration – a novel treatment for hyperactive bladder in the rat. Urology. 2003;61:656–663.
42.
Chuang YC, Lee WC, Chiang PH. Intravesical liposome versus oral pentosan polysulfate for interstitial cystitis/painful bladder syndrome. J. Urol. 2009;182:1393–1400.
43.
Kaufman J, Lipella Pharmaceuticals Inc. Efficacy of Intravesical LP08 in patients with interstitial cystitis/painful bladder syndrome. IN: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000. Available from: http://​clinicaltrials.​gov/​show/​NCT01393223.​ NCT identifier: 01393223. Cited 2013 Sept
44.
Parsons CL. Evidence-based strategies for recognizing and managing interstitial cystitis. Contemp. Urol. 2003;15(2):22–35
Metadata
Title
Current Recommendations for Bladder Instillation Therapy in the Treatment of Interstitial Cystitis/Bladder Pain Syndrome
Authors
Marc A. Colaco
Robert J. Evans
Publication date
01-10-2013
Publisher
Springer US
Published in
Current Urology Reports / Issue 5/2013
Print ISSN: 1527-2737
Electronic ISSN: 1534-6285
DOI
https://doi.org/10.1007/s11934-013-0369-y

Other articles of this Issue 5/2013

Current Urology Reports 5/2013 Go to the issue

Surgical Techniques (J Cadeddu and A Stenzl, Section Editors)

Zero-Ischemia Minimally Invasive Partial Nephrectomy

Lower Urinary Tract Symptoms and Voiding Dysfunction (G Badlani and H Goldman, Section Editors)

β3-Receptor Agonists for Overactive Bladder—New Frontier or More of the Same?

Lower Urinary Tract Symptoms and Voiding Dysfunction (G Badlani and H Goldman, Section Editors)

Overactive Bladder in Elderly Men: Epidemiology, Evaluation, Clinical Effects, and Management

Lower Urinary Tract Symptoms and Voiding Dysfunction (G Badlani and H Goldman, Section Editors)

Retropubic Versus Transobturator Slings—Are the Outcomes Changing with Time?

Lower Urinary Tract Symptoms and Voiding Dysfunction (G Badlani and H Goldman, Section Editors)

Update on Behavioral and Physical Therapies for Incontinence and Overactive Bladder: The Role of Pelvic Floor Muscle Training

Surgical Techniques (J Cadeddu and A Stenzl, Section Editors)

Cell-Based Therapy for the Deficient Urinary Sphincter